Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189] (Vaccine: X (2022) 11, (S2590136222000493), (10.1016/j.jvacx.2022.100189))

Sáez-Llorens X.; Lanata C.; Aranguren E.; Celis C.R.; Cornejo R.; DeAntonio R.; Ecker L.; Garrido D.; Gil A.I.; Gonzales M.; Hess-Holtz M.; Leroux-Roels G.; Junker H.; Kays S.-K.; Koch S.D.; Lazzaro S.; Mann P.; Quintini G.; Srivastava B.; Vahrenhorst D.; von Eisenhart-Rothe P.; Wolz O.-O.; Oostvogels L. · Vaccine: X (2023) · DOI: 10.1016/j.jvacx.2023.100307

Resumen

The authors regret that the legend for Supplementary Fig. 1 states CD8+ cells, but the graphs provided in the Supplementary Information were for CD4+. The correct graphs for CD8+ cells are shown below:[Formula presented] The authors would like to apologise for any inconvenience caused.